Biocryst pharmaceuticals inc (BCRX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net loss

-108,897

-101,252

-65,782

-55,144

-43,019

-45,189

-30,108

-39,081

-56,948

-33,853

-13,451

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

724

770

704

483

180

177

304

628

886

2,267

1,613

Loss (gain) on disposal of property and equipment

-

-7

12

-17

0

-27

47

-

-

-

-

Stock-based compensation expense

17,719

9,396

12,621

8,487

9,705

10,177

4,368

4,167

4,772

6,302

5,525

Amortization of debt issuance costs

1,278

885

876

558

439

439

439

439

356

-

-

Amortization of premium/discount on investments

117

110

157

523

570

150

-

-

-

-

-

Change in fair value of foreign currency derivative

-347

-1,049

-966

811

-564

5,487

5,294

-749

-4,000

-

-

Deferred revenue

1,899

-7,079

-1,722

-1,631

1,199

4,429

-1,103

-9,577

-1,552

-2,497

-2,565

Changes in operating assets and liabilities:
Receivables

17,853

-1,824

-2,651

2,525

-3,247

7,375

-2,447

-1,269

-24,396

-3,495

21,740

Inventory

-1,649

1,649

-500

-1,112

929

683

0

-263

-635

-5,383

6,281

Prepaid expenses and other assets

1,364

866

-951

-3,702

-637

2,093

620

623

-626

-51

-81

Deferred collaboration expense

-

-

-

-71

102

-59

-5,133

-2,301

-1,309

220

-377

Accounts payable and accrued expenses

11,741

4,487

3,842

-10,524

13,676

4,656

-2,049

2,068

-10,731

-9,483

20,223

Interest payable

3,056

-247

3,105

2,244

717

2,162

-

-

-

-

-

Net cash used in operating activities

-89,584

-92,565

-41,143

-53,438

-13,116

-38,551

-26,530

-37,397

-32,251

-28,555

-16,218

Investing activities
Acquisition of property and equipment

343

366

328

5,277

5,122

106

30

113

55

325

604

Proceeds from sale of property and equipment

-

-

12

4

0

0

50

-

-

-

-

Change in restricted cash

-

-

-

-

1,462

-1

-157

-317

-

-

625

Purchases of investments

3,018

62,614

107,787

14,106

53,830

73,875

23,974

16,153

45,500

55,909

54,103

Sales and maturities of investments

81,295

67,748

43,461

42,652

42,410

34,000

20,330

40,833

56,873

56,455

42,437

Net cash provided by investing activities

77,934

4,768

-64,642

23,273

-18,004

-39,980

-3,467

24,884

11,318

221

-12,895

Financing activities
Proceeds from senior credit facility

19,477

10,353

-

22,658

0

0

-

-

-

-

-

Sale of common stock, net

58,500

53,400

134,000

-

0

106,600

23,633

17,805

1,027

-

45,740

Sale of pre-funded warrants

19,882

-

-

-

-

-

-

-

-

-

-

Net proceeds from common stock issued under stock-based compensation plans

1,239

2,852

1,581

317

5,479

5,307

1,333

534

278

553

2,117

Payment of senior credit facility

-

4,025

-

-

-

-

-

-

-

-

-

(Decrease) increase in lease financing obligation

-

-76

122

329

0

0

124

321

300

283

194

Receipt of foreign currency derivative collateral

-

-

-

-

-

-

5,180

-1,700

-3,480

-

-

Purchases of treasury stock

-

-

-

-

-

-

-

-

61

5

155

Issuance of non-recourse notes payable, net

-

-

-

-

-

-

-

-

25,691

-

-

Net cash provided by financing activities

99,098

62,504

135,703

23,304

5,479

111,907

30,270

16,960

23,755

831

47,896

Increase (decrease) in cash, cash equivalents and restricted cash

87,448

-25,293

29,918

-6,861

-25,641

33,376

273

4,447

2,822

-27,503

18,783